Evotec Investor Day Presentation Deck

PAGE 93 evotec MOLECULE DISCOVERY J.DISCOVERY Partner or client antibodies from animals or people are improved for manufacturing and formulation Abacus - an in silico computational toolset of ML algorithms Abacus Antibody Fv with hot spots displayed IGHV3-30-01 o IGMV3-30-3-01 01GHV3-33-01 MOLECULE DESIGN J.MD™ 67 TM KV67 ASFLYSGVPSRFSGS KV:81 KV:56 YSASFLYSGVPSRF KV78 2.18 KV:52 PKLLIYSASFLYSGV KV:74 2.25 KV51 APKLLIYSASFLYSG KV 73 2.07 KV:50 LIYSASFLYS KV:72 1.84 Hot spot tables Clading Germline Switching 1.88 1.95 Sequence Predicted binding to HLA DRB!* start peptide end 0101 0301 0401 0701 0801 1101 1301 1501 KV.57 YSASFLYSGVPSRFS KV:79 KV-58 SASFLYSGVPSRFSG KV:80 2.07 3.48 1.90 1.69 3.33 1.77 1.83 Variable Region Hotspots gut Export to Exca Export SV for HotSpot Highlighting in MOE Covariance Ste Coverance Site Covariance Site Non-Standard N-La Cycosylation Site Potential Isomerization Site (CDR) Potental Deamidation Site (CDR) alignments 1.74 CONSENSUS Structure-o ipilimumab Odenosumab ML Tier 2 T2 based gantenerumab Ter 2 ASN a 3.56 4.05 Predictor 4.04 PROCESS & PRODUCT DESIGN JP3 Immunogenicity Chain Kappe G HC GMC G HC DG HC lgG: HC mmomm teprotumumab E robatumumab Kapp Variable Heavy Variable Heavy Varable Heavy Variable IVLTQ SP Germline ipilimumab_LC Analysis Framework 3 103 Framework HS Framework 1 M3 CDR 2 CDR 3 KV FR1 LS ASN # ASN Location TTTTT ADDLX Score hu IGKV3-20 100.0% ohu IGKV3D-20 97.1% hu IGKV3-11 95.7% hu IGKV3D-11 94.3 % hu IGKV3D-7 92.9% HV:59.65 198:72.73 H112 113 Molecular optimisation builds in quality SP Qmax N E24 ton $3 veslation max NT >KV1:39 GERAT S Molecules optimised for Expression in cells ● MANUFACTURING DESIGN J.PODⓇ • Purification . Formulation ● Long-term stability

View entire presentation